Werewolf Therapeutics announced a 64% workforce reduction and the resignation of its CFO and CMO, resulting in an estimated $4.1 million one-time charge in Q1 2026. The Company appointed Michael Urban as principal financial officer and is evaluating strategic alternatives for its pipeline.
Key takeaways
Board approved a reduction in force affecting 64% of the workforce on February 9, 2026.
Company expects to record a one-time charge of approximately $4.1 million in Q1 2026 for the restructuring.
CFO Timothy W. Trost and CMO Dr. Randi Isaacs resigned effective February 13, 2026, and will transition to consulting roles.
Michael Urban was appointed as principal financial officer and principal accounting officer effective February 13, 2026.
Company is evaluating strategic alternatives, including partnerships for WTX-124 and WTX-330 INDUKINE programs.